Ind-Swift Laboratories has incorporated wholly owned subsidiary (WOS) in the name and style of ‘ISLL Middle East L.L.C-FZ’ in Dubai, United Arab Emirates (UAE). The certificate of incorporation has been received on May 17, 2024 from the Registrar of Companies of the Meydan - Free Zone.
The WOS intends to strategically invest in pharmaceutical and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures. Additionally, the Company aims to establish and operate pharmaceutical manufacturing units.
Ind-Swift Laboratories is global manufacturer of Active Pharmaceutical Ingredients (API), Intermediates and formulations (through group collaboration).
